Loading provider…
Loading provider…
Neurology Physician in Detroit, MI
NPI: 1427171677Primary Practice Location
HENRY FORD HEALTH HOSPITAL
2799 W Grand Blvd, Detroit, MI
Primary Employer
Henry Ford Health
henryford.com
HQ Phone
Get M.D., PH.D. Mirela's Phone Numberphone_androidMobile
Get M.D., PH.D. Mirela's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMI State Medical License
FL State Medical License
2022
MI State Medical License
2002 - 2026

American Board of Psychiatry and Neurology
Neurology
College of Human Medicine - Grand Rapids
humanmedicine.msu.edu
Neurology
Until 2023
Henry Ford Health/Henry Ford Hospital
Residency • Neurology
2003 - 2006
Internship • Transitional Year
2002 - 2003
Wayne State University School Of Medicine
med.wayne.edu
PhD • Anatomy and Cell Biology
1999 - 2002
Neurology
Until 2011
Carol Davila University of Medicine and Pharmacy
Medical School
Until 1988
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 55 | 62 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 36 | 39 |
| 3 | 99204New patient office or other outpatient visit, 45-59 minutes | 18 | 18 |
| 4 | 99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 17 | 17 |
| 5 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 13 | 14 |
Authors: Jolliffe, Evan A, Guo, Yong, Hardy, Todd A, Morris, P Pearse, Flanagan, Eoin P, Lucchinetti, Claudia F, Tobin, W Oliver
Journal: Neurology
Publication Date: 2021-05-19
Lead Sponsor: EMD Serono Research & Development Institute, Inc.
Collaborators: Merck KGaA, Darmstadt, Germany
Intervention / Treatment: DRUG: Cladribine
Lead Sponsor: Novartis Pharmaceuticals
Intervention / Treatment: DRUG: Ofatumumab, DRUG: Disease modifying treatment (DMT)
Lead Sponsor: Immunic AG
Intervention / Treatment: DRUG: IMU-838, DRUG: Placebo matching IMU-838